Lindynette 20 (Ethinylestradiol, Gestodene)

• Lindynette 20, a combined oral contraceptive, is employed in the hormonal contraception pathway to reliably prevent unintended pregnancy and to provide additional menstrual cycle benefits.
• Pregnancy prevention: provides reliable birth control by suppressing ovulation.
• Menstrual cycle regulation: helps achieve more predictable monthly bleeding patterns.
• Hormonal contraception therapy: offers a convenient daily regimen for women seeking estrogen‑progestogen based contraception.

• The tablet combines ethinylestradiol, a synthetic estrogen, with gestodene, a third‑generation progestogen. Both bind to estrogen and progesterone receptors, suppressing the hypothalamic‑pituitary‑ovarian axis and reducing luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) secretion, thereby preventing follicular development and ovulation. Gestodene also thickens cervical mucus, and the hormonal combination induces endometrial changes that are unfavorable for implantation.

Lindynette 20 may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: swelling or discomfort.
• Spotting between periods: irregular light bleeding.
• Mood changes: irritability or emotional fluctuations.
• Weight gain: slight increase in body weight.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Arterial thrombosis: stroke or myocardial infarction.
• Hypertension: significant rise in blood pressure.
• Severe liver dysfunction: jaundice or hepatic failure.
• Allergic reactions: rash, swelling, or anaphylaxis.
• Visual disturbances: blurred vision or loss of sight.

Before prescribing Lindynette 20, clinicians should consider several precautionary measures to ensure patient safety.

• Contraindicated in pregnancy: product is category X and must not be used by pregnant women.
• Avoid in smokers over 35 years: increased risk of thromboembolic events.
• Assess cardiovascular risk: history of thrombosis, hypertension, or heart disease requires careful evaluation.
• Monitor blood pressure: oral contraceptives may elevate systolic and diastolic pressures.
• Review liver function: hepatic impairment can affect hormone metabolism.
• Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Lindynette 20 can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): markedly reduce contraceptive efficacy.
• Rifampicin and other strong CYP3A inducers: may render the tablet ineffective.

Moderate Interactions (Monitor Closely)

• Antiretroviral protease inhibitors (e.g., ritonavir): can increase hormone levels, requiring monitoring.
• Certain antibiotics such as tetracycline: may slightly lower plasma concentrations of the hormones.
• St. John’s wort: may modestly decrease contraceptive effectiveness.